194 related articles for article (PubMed ID: 24975891)
1. Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.
Ito K; Takeshima A; Shishido K; Wakasa M; Kumata C; Matsuzaka K; Nakajima Y; Ogata H
Ther Apher Dial; 2014 Jun; 18 Suppl 2():19-23. PubMed ID: 24975891
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.
Gen S; Sasaki T; Saito K; Nobe K; Nodaira Y; Ikeda N
Ther Apher Dial; 2014 Jun; 18 Suppl 2():8-12. PubMed ID: 24975889
[TBL] [Abstract][Full Text] [Related]
3. Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.
Furukawa K; Ikawa T; Yokoi S; Yokouchi S; Kato K; Ueno M; Takahashi J
Ther Apher Dial; 2014 Jun; 18 Suppl 2():2-7. PubMed ID: 24975888
[TBL] [Abstract][Full Text] [Related]
4. Clinical experiences of bixalomer usage at our hospital.
Shima H; Makino R; Hata K; Ban A; Funao K; Sugita S; Furumitsu Y; Inoue K; Yoshimoto M; Okamura M
Ther Apher Dial; 2014 Jun; 18 Suppl 2():13-8. PubMed ID: 24975890
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients.
Akizawa T; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2013 Dec; 17(6):612-9. PubMed ID: 24330556
[TBL] [Abstract][Full Text] [Related]
9. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
10. Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis.
Hatakeyama S; Murasawa H; Narita T; Oikawa M; Fujita N; Iwamura H; Mikami J; Kojima Y; Sato T; Fukushi K; Ishibashi Y; Hashimoto Y; Koie T; Saitoh H; Funyu T; Ohyama C
BMC Nephrol; 2013 Oct; 14():222. PubMed ID: 24119202
[TBL] [Abstract][Full Text] [Related]
11. Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer.
Sanai T; Tada H; Ono T; Fukumitsu T
Hemodial Int; 2015 Jan; 19(1):54-9. PubMed ID: 24980286
[TBL] [Abstract][Full Text] [Related]
12. Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.
Kasai S; Sato K; Murata Y; Kinoshita Y
Ther Apher Dial; 2012 Aug; 16(4):341-9. PubMed ID: 22817122
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Safety and Efficacy of Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis.
Akizawa T; Tsukada J; Kameoka C; Kuroishi K; Yamaguchi Y
Ther Apher Dial; 2017 Apr; 21(2):173-179. PubMed ID: 28194884
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.
Ketteler M; Rix M; Fan S; Pritchard N; Oestergaard O; Chasan-Taber S; Heaton J; Duggal A; Kalra PA
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1125-30. PubMed ID: 18450923
[TBL] [Abstract][Full Text] [Related]
18. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
[TBL] [Abstract][Full Text] [Related]
20. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
Taniguchi K; Kakuta H
Eur J Pharmacol; 2015 Nov; 766():129-34. PubMed ID: 26452517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
